title: Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment.
abstract: Sequential changes in the phenotype of prostatic lesions and the impact of additional carcinogen treatment or castration on development and progression of prostate cancers were examined in probasin/simian virus 40 (SV40) T antigen transgenic (TG) rats. Non-invasive prostate adenocarcinomas were evident in all lobes at 15 weeks of age. Invasive tumors were limited to the anterior lobe at this time point and were found in all lobes in an age-dependent manner thereafter. No metastasis was apparent at any age. Additional carcinogen treatment or castration did not enhance progression or generate selective growth of hormone-independent prostate cancer cells. These results suggest that our TG rats are suitable for clarification of mechanisms in early stages of prostate carcinogenesis, that is, from prostatic intraepithelial neoplasia (PIN) to non-invasive and then invasive lesions.
authors.affiliation: Department of Experimental Pathology and Tumor Biology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601. ymcho@med.nagoya-cu.ac.jp
authors.forename: Young-Man
authors.initials: YM
authors.lastname: Cho
authors.forename: Satoru
authors.initials: S
authors.lastname: Takahashi
authors.forename: Makoto
authors.initials: M
authors.lastname: Asamoto
authors.forename: Shugo
authors.initials: S
authors.lastname: Suzuki
authors.forename: Shingo
authors.initials: S
authors.lastname: Inaguma
authors.forename: Naomi
authors.initials: N
authors.lastname: Hokaiwado
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Shirai
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology*; D000367:Age Factors; D000611:Aminobiphenyl Compounds / Q000633:toxicity*; D000726:Androgen Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000727:Androgen-Binding Protein / Q000235:genetics* / Q000502:physiology; D000818:Animals; D030801:Animals, Genetically Modified; D000952:Antigens, Polyomavirus Transforming / Q000032:analysis / Q000235:genetics* / Q000502:physiology; D002273:Carcinogens / Q000633:toxicity*; D018450:Disease Progression; D004343:Drug Implants; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000627:therapeutic use; D006579:Heterozygote; D007093:Imidazoles / Q000633:toxicity*; D019394:Ki-67 Antigen / Q000032:analysis; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000235:genetics; D009363:Neoplasm Proteins / Q000032:analysis; D009919:Orchiectomy; D010641:Phenotype; D011467:Prostate / Q000254:growth & development / Q000473:pathology*; D019048:Prostatic Intraepithelial Neoplasia / Q000235:genetics / Q000473:pathology; D011471:Prostatic Neoplasms / Q000473:pathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011944:Receptors, Androgen / Q000032:analysis; D013739:Testosterone / Q000008:administration & dosage / Q000633:toxicity*; D014062:Tongue Neoplasms / Q000235:genetics
chemical_list: D000611:Aminobiphenyl Compounds; D000726:Androgen Antagonists; D000727:Androgen-Binding Protein; D000952:Antigens, Polyomavirus Transforming; D002273:Carcinogens; D004343:Drug Implants; D007093:Imidazoles; D019394:Ki-67 Antigen; D009363:Neoplasm Proteins; D011944:Receptors, Androgen; C027519:probasin; C001042:2',3-dimethyl-4-aminobiphenyl; D013739:Testosterone; D004997:Ethinyl Estradiol; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine